PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments
Silexion Therapeutics (NASDAQ: SLXN) has unveiled promising preclinical data for SIL-204, its next-generation siRNA candidate targeting KRAS-driven cancers. The data demonstrates significant synergy between SIL-204 and first-line chemotherapy agents, including 5-fluorouracil, irinotecan, and gemcitabine.
In human pancreatic tumor cell models with KRAS G12D mutations, SIL-204 enhanced the effectiveness of standard therapies, showing greater reductions in cancer cell confluence compared to chemotherapy alone. This is particularly significant as KRAS mutations are present in over 90% of pancreatic cancer cases.
Building on its first-generation LODER™ platform's success in Phase 2 trials, SIL-204 targets a broader spectrum of KRAS mutations. The company plans to begin toxicology studies soon, with Phase 2/3 trials scheduled for 2026. Additionally, Silexion announced a $5 million public offering to support its research efforts.
Silexion Therapeutics (NASDAQ: SLXN) ha svelato dati preclinici promettenti per SIL-204, il suo candidato siRNA di nuova generazione che mira ai tumori guidati da KRAS. I dati dimostrano una significativa sinergia tra SIL-204 e gli agenti chemioterapici di prima linea, inclusi 5-fluorouracile, irinotecano e gemcitabina.
Nei modelli cellulari tumorali pancreatici umani con mutazioni KRAS G12D, SIL-204 ha aumentato l'efficacia delle terapie standard, mostrando una riduzione maggiore della confluenza cellulare tumorale rispetto alla chemioterapia da sola. Questo è particolarmente significativo, poiché le mutazioni KRAS sono presenti in oltre il 90% dei casi di cancro pancreatico.
Basandosi sul successo della sua piattaforma di prima generazione LODER™ negli studi di Fase 2, SIL-204 mira a un più ampio spettro di mutazioni KRAS. L'azienda prevede di avviare presto studi di tossicologia, con studi di Fase 2/3 programmati per il 2026. Inoltre, Silexion ha annunciato un'offerta pubblica di 5 milioni di dollari per supportare i suoi sforzi di ricerca.
Silexion Therapeutics (NASDAQ: SLXN) ha revelado datos preclínicos prometedores para SIL-204, su candidato de siRNA de próxima generación dirigido a cánceres impulsados por KRAS. Los datos demuestran una sinergia significativa entre SIL-204 y los agentes de quimioterapia de primera línea, incluyendo 5-fluorouracilo, irinotecano y gemcitabina.
En modelos celulares de tumores pancreáticos humanos con mutaciones KRAS G12D, SIL-204 aumentó la efectividad de las terapias estándar, mostrando mayores reducciones en la confluencia celular cancerosa en comparación con la quimioterapia sola. Esto es particularmente significativo, ya que las mutaciones de KRAS están presentes en más del 90% de los casos de cáncer pancreático.
Construyendo sobre el éxito de su plataforma de primera generación LODER™ en ensayos de Fase 2, SIL-204 tiene como objetivo un espectro más amplio de mutaciones KRAS. La compañía planea comenzar pronto estudios de toxicología, con ensayos de Fase 2/3 programados para 2026. Además, Silexion anunció una oferta pública de 5 millones de dólares para apoyar sus esfuerzos de investigación.
시렉시온 치료제 (NASDAQ: SLXN)은 SIL-204의 유망한 전임상 데이터를 공개했습니다. SIL-204는 KRAS 유도암을 겨냥한 차세대 siRNA 후보물질입니다. 이 데이터는 SIL-204와 5-플루오로우라실, 이리노테칸, 그리고 젬시타빈을 포함한 1차 화학요법제 간의 중요한 시너지를 보여줍니다.
KRAS G12D 변이가 있는 인간 췌장 종양 세포 모델에서, SIL-204는 표준 치료제의 효과를 향상시켜 화학요법 단독에 비해 암세포의 군집성이 더욱 감소하는 모습을 보였습니다. 이는 KRAS 변이가 췌장암 환자의 90% 이상에서 발견되기 때문에 특히 중요합니다.
1세대 LODER™ 플랫폼이 2상 시험에서 성공을 거두었던 것을 바탕으로, SIL-204는 더욱 다양한 KRAS 변이를 겨냥합니다. 회사는 곧 독성학 연구를 시작할 계획이며, 2026년에는 2상/3상 시험이 예정되어 있습니다. 또한 시렉시온은 연구 노력을 지원하기 위해 500만 달러의 공모를 발표했습니다.
Silexion Therapeutics (NASDAQ: SLXN) a dévoilé des données précliniques prometteuses pour SIL-204, son candidat siRNA de nouvelle génération ciblant les cancers dirigés par KRAS. Les données montrent une synergie significative entre SIL-204 et les agents de chimiothérapie de première ligne, y compris le 5-fluorouracile, l'irinotécan, et la gemcitabine.
Dans des modèles de cellules tumorales pancréatiques humaines avec mutations KRAS G12D, SIL-204 a amélioré l'efficacité des thérapies standard, montrant des réductions plus importantes dans la confluence des cellules cancéreuses par rapport à la chimiothérapie seule. Cela est particulièrement significatif car les mutations KRAS sont présentes dans plus de 90 % des cas de cancer du pancréas.
S'appuyant sur le succès de sa plateforme de première génération LODER™ dans les essais de Phase 2, SIL-204 vise un plus large éventail de mutations KRAS. La société prévoit de commencer bientôt des études de toxicologie, avec des essais de Phase 2/3 programmés pour 2026. De plus, Silexion a annoncé une offre publique de 5 millions de dollars pour soutenir ses efforts de recherche.
Silexion Therapeutics (NASDAQ: SLXN) hat vielversprechende präklinische Daten für SIL-204 veröffentlicht, seinen siRNA-Kandidaten der nächsten Generation, der auf KRAS-gesteuerte Krebserkrankungen abzielt. Die Daten zeigen eine signifikante Synergie zwischen SIL-204 und Chemotherapie-Mitteln der ersten Linie, einschließlich 5-Fluoruracil, Irinotecan und Gemcitabin.
In menschlichen Modellen von Bauchspeicheldrüsen-Tumorzellen mit KRAS G12D-Mutationen erhöhte SIL-204 die Wirksamkeit der Standardtherapien und zeigte größere Reduktionen in der Zellkonfluenz im Vergleich zur alleinigen Chemotherapie. Dies ist besonders bedeutsam, da KRAS-Mutationen in über 90% der Fälle von Bauchspeicheldrüsenkrebs vorkommen.
Aufbauend auf dem Erfolg der ersten Generation der LODER™-Plattform in Phase 2 Studien, zielt SIL-204 auf ein breiteres Spektrum von KRAS-Mutationen ab. Das Unternehmen plant, bald toxikologische Studien zu beginnen, mit Phase 2/3 Studien, die für 2026 anstehen. Darüber hinaus gab Silexion eine öffentliche Aktienemission über 5 Millionen Dollar zur Unterstützung seiner Forschungsbemühungen bekannt.
- None.
- None.
KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights SIL-204’s ability to enhance first-line therapies, showcasing its potential to transform outcomes in these hard-to-treat cancers.
The newly released data reveal significant synergy between SIL-204 and first-line chemotherapy agents, including 5-fluorouracil, irinotecan, and gemcitabine. In human pancreatic tumor cell models harboring KRAS G12D mutations, SIL-204 amplified the efficacy of these standard therapies, resulting in greater reductions in cancer cell confluence compared to chemotherapy alone. This underscores SIL-204’s potential to enhance treatment regimens for pancreatic cancer and other KRAS-driven cancers, potentially addressing a substantial unmet medical need.
Building on the success of its first-generation LODER™ platform, which improved overall survival in Phase 2 trials, SIL-204 takes Silexion’s RNAi approach further by targeting a broader spectrum of KRAS mutations. With toxicology studies set to begin soon and Phase 2/3 trials planned for 2026, Silexion remains on track to advance its groundbreaking candidate into the clinic.
Shortly releasing this new data, Silexion also announced the pricing of a
As KRAS-driven cancers continue to be among the most aggressive and elusive to treat, Silexion’s progress with SIL-204 positions it as an important innovator to watch in the precision oncology space, offering hope for transformative therapies that could redefine cancer care.
Subscribe for more updates from PESG:
https://www.pesgresearch.com/subscribe
PESG is a commercial digital news and coverage brand. PESG’s market updates are intended to summarize news developments from issuers it engages with and thus include partner advertising content on behalf of the mentioned issuer [SLXN]. They are not intended to serve as financial or investment advice. Please see our full terms, disclaimers and compensation disclosures here: redditwire.com/terms. PESG is part of the Wall Street Wire network, which is operated by an IR provider for commercial purposes. Our content may include forward looking statements about the significance or impact an announcement or development may have on the future of a company or industry as well as other similar statements which may not come to fruition. We advise all readers refer to our full terms in the above link.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116874895/en/
PESG Editorial Desk
ronald@futuremarketsresearch.com
Source: PESG
FAQ
What are the key findings from Silexion's (SLXN) SIL-204 preclinical trials?
When will Silexion (SLXN) begin Phase 2/3 trials for SIL-204?
How much funding did Silexion (SLXN) secure in its latest public offering?
What percentage of pancreatic cancer cases involve KRAS mutations targeted by Silexion's SIL-204?
Which chemotherapy agents showed synergy with Silexion's (SLXN) SIL-204?
